AZTherapies

Az Therapies

Pharmaceuticals, 200 Clarendon St Ste 1700, Boston, Massachusetts, 02116, United States, 11-50 Employees

aztherapies.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is AZTHERAPIES

AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company developing treatments for devastating neurological conditions. We are using an innovative, multi-modal approa...

Read More

map
  • 200 Clarendon St Ste 1700, Boston, Massachusetts, 02116, United States Headquarters: 200 Clarendon St Ste 1700, Boston, Massachusetts, 02116, United States
  • 2011 Date Founded: 2011
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $5 Million to $10 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834 | NAICS Code: 561110 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from AZTHERAPIES

AZTherapies Org Chart and Mapping

Employees

Breana Loreaux

Technical Operations Manager

Katie Barrett

Associate Director of Clinical Operations

Levi Watkin

Research Immunologist

David Brazier

Senior Director , Clinical Operations

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding AZTherapies

Answer: AZTherapies's headquarters are located at 200 Clarendon St Ste 1700, Boston, Massachusetts, 02116, United States

Answer: AZTherapies's phone number is 61********

Answer: AZTherapies's official website is https://aztherapies.com

Answer: AZTherapies's revenue is $5 Million to $10 Million

Answer: AZTherapies's SIC: 2834

Answer: AZTherapies's NAICS: 561110

Answer: AZTherapies has 11-50 employees

Answer: AZTherapies is in Pharmaceuticals

Answer: AZTherapies contact info: Phone number: 61******** Website: https://aztherapies.com

Answer: AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company developing treatments for devastating neurological conditions. We are using an innovative, multi-modal approach that recognizes neuro-inflammation as a root cause of neuro-degeneration, leveraging the ability of cromolyn, a small molecule with a well-characterized safety profile, to shift the brains innate immune cells from a pro-inflammatory to neuroprotective state. We are advancing a pipeline of candidates in Alzheimer's Disease, amyotrophic lateral sclerosis (ALS) and post-ischemic stroke cognitive impairment.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access